{"id":1014150,"date":"2026-10-27T11:27:03","date_gmt":"2026-10-27T15:27:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cc-upcoming-deadline-suewallst-alerts-the-chemours-company-stockholders-of-securities-class-action-contact-the-firm\/"},"modified":"2026-10-27T11:27:03","modified_gmt":"2026-10-27T15:27:03","slug":"cc-upcoming-deadline-suewallst-alerts-the-chemours-company-stockholders-of-securities-class-action-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cc-upcoming-deadline-suewallst-alerts-the-chemours-company-stockholders-of-securities-class-action-contact-the-firm\/","title":{"rendered":"CC UPCOMING DEADLINE: SueWallSt Alerts The Chemours Company Stockholders of Securities Class Action – Contact the Firm"},"content":{"rendered":"

\nA federal refrigerant mandate allegedly anchored Chemours’ Opteon growth story, but the lawsuit claims the 2025 AIM Act transition left an overstocked aftermarket channel that undercut the Company’s 2026 outlook.
\n<\/h2>\n
\n

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) — SueWallSt notifies shareholders of The Chemours Company (NYSE: CC) that a securities class action is pending on behalf of investors who purchased Chemours securities between February 20, 2026 and August 4, 2026.\u00a0Submit your information now<\/a> or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/a> or (888) SueWallSt.<\/p>\n

Chemours stock fell 18.63% to close at $14.59 per share on August 5, 2026. The decline followed the Company’s cut to its 2026 adjusted EBITDA guidance, from a range of $800 million to $900 million down to $775 million to $825 million, and a reported 4% second-quarter volume decline. IMPORTANT DATE: December 7, 2026<\/strong> is the deadline for investors to seek appointment as lead plaintiff.<\/p>\n

\n When a Federal Mandate Becomes a Growth Pitch<\/strong>\n <\/p>\n

Congress enacted the American Innovation and Manufacturing Act (U.S. AIM Act) in December 2020. The law directs the U.S. Environmental Protection Agency to oversee a transition from legacy refrigerants to lower-impact alternatives such as Chemours’ Opteon line. Chemours told investors in its SEC filings that “[g]rowth in our Thermal & Specialized Solutions segment is supported in part by the adoption of the [U.S. AIM Act] in the U.S.”<\/p>\n

The lawsuit contends that management continued to present this regulatory adoption as a source of Opteon demand heading into 2026. According to the complaint, the 2025 phase of the transition had already led aftermarket customers to overstock. Plaintiffs allege the resulting oversupply left the reaffirmed 2026 guidance without a reasonable basis.<\/p>\n

\n Chemours AIM Act Regulatory Exposure: What the Case Alleges<\/strong>\n <\/p>\n